Evidence map›Paper›PMID 42415021›Full record

ArticleMicrobial cell factories2026

Metabolic engineering of Escherichia coli strains for the in vivo phosphorylase-mediated synthesis of disaccharides.

Pietro Tedesco, Julien Durand, Laurence Tarquis, Gabrielle Potocki-Veronese, Fabien Létisse

Abstract read
In one paragraph

Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pietro Tedesco *TBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, 31077, France.
Julien Durand *TBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, 31077, France.
Laurence TarquisTBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, 31077, France.
Gabrielle Potocki-VeroneseTBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, 31077, France. veronese@insa-toulouse.fr.
Fabien LétisseInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France. fabien.letisse@utoulouse.fr.ORCID http://orcid.org/0000-0002-1490-0152

Funding

Agence Nationale de la Recherche ANR-16-CE20-0006-03
6 · The paper itself

Abstract

backgroundEnzymatic synthesis of rare disaccharides by reverse-phosphorolysis is a potentially sustainable route to produce high-value glycosides for human health and nutrition. In vivo synthesis using microorganisms expressing recombinant glycoside phosphorylases is an attractive strategy, as it may overcome key limitations associated with conventional chemical and enzymatic approaches. However, successful implementation requires dedicated metabolic chassis enabling efficient precursor supply and carbon flux redirection. In Escherichia coli, inactivation of the phosphotransferase system (PTS) combined with deletion of pfkA constitutes a promising strategy to decouple sugar uptake from their concomitant phosphorylation, promote the accumulation of key sugar phosphates, and enable reverse biosynthetic pathways for oligosaccharide production.

resultsWe first established β-1,2-mannobiose production as a proof of concept. The expression of heterologous permease GalP restored the growth on mannose in a PTS⁻ background and allowed mannose into the reverse biosynthetic pathway. Deletion of pfkA, which promotes intracellular accumulation of glucose 1-phosphate (G1P) and mannose 1-phosphate (M1P), combined with the expression of a β-1,2-mannoside-phosphorylase, enabled the direct synthesis of β-1,2-mannobiose from mannose. The pfkA deletion significantly increased product titers (> 0.6 g·L⁻¹) and yields (up to 9% g/g mannose), reflecting an efficient redistribution of carbon fluxes toward disaccharide formation. Furthermore, mixed-substrate cultures using glycerol as the carbon and energy source, together with additional metabolic engineering, enabled partial growth-production decoupling and redirected mannose utilization primarily toward product synthesis, achieving yields of up to 60%. The same metabolic chassis was further employed for the production of β-1,4-mannobiose and laminaribiose through the expression of a β-mannoside-phosphorylase and a laminaribiose-phosphorylase, using mannose and glucose as substrates, respectively.

conclusionHere, we report the metabolic engineering of Escherichia coli for in vivo production of oligosaccharides with different glycosidic linkages from hexose sugars. These results demonstrate the modularity and efficiency of the proposed platform for fermentative production of non-conventional oligosaccharides and expand the scope of metabolic engineering strategies for glycoside biosynthesis.

Indexed as

DisaccharidesEscherichia coliMetabolic EngineeringPhosphorylasesEscherichia coli ProteinsMannansMannoseDisaccharidesEscherichia coli ProteinsMannansmannobioseMannosePhosphorylasesCarbon flux controlGlycoside phosphorylasesGrowth–production decouplingMetabolic engineeringOligosaccharidesReverse phosphorolysisβ-mannobiose

Identifiers

PMID42415021
PMCPMC13625282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.